Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

15.08
Delayed Data
As of 4:02pm ET
 -0.55 / -3.52%
Today’s Change
13.77
Today|||52-Week Range
119.87
-85.16%
Year-to-Date
Cramer: Make a Deal or Face the Wheel
7:03pm / TheStreet.com - Paid Partner Content
Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November
Dec 06 / MotleyFool.com - Paid Partner Content
Why Valeant Pharmaceuticals (VRX) Could Be Positioned for a Slump
12:29pm / Zacks.com - Paid Partner Content
Surprise! The SEC Isn't Happy With Valeant Pharmaceuticals Again
Dec 05 / MotleyFool.com - Paid Partner Content
Trump warns Wall Street: I'm going to cut drug prices
10:40am / CNNMoney.com
3 Prime Reasons Valeant Pharmaceuticals Intl. Inc. Shares Dove 11% in November
Dec 05 / MotleyFool.com - Paid Partner Content
24 Questions With Value Investor Jacob Taylor of the UC Davis Graduate School of Mana...
Dec 06 / GuruFocus News - Paid Partner Content
Is Mylan Being Really Smart -- Or Really Arrogant?
Dec 04 / MotleyFool.com - Paid Partner Content
Questions Mount at Teva Amid C-suite Change
Dec 06 / TheStreet.com - Paid Partner Content
3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017
Dec 01 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close15.63
Today’s open15.42
Day’s range14.82 - 15.43
Volume19,265,847
Average volume (3 months)22,239,692
Market cap$5.3B
Dividend yield--
Data as of 4:02pm ET, 12/07/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-46.13%
Earnings growth (next 5 years)+9.80%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book0.91

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc-2.36-4.39%
IONSIonis Pharmaceutical...-1.45-3.06%
UTHRUnited Therapeutics ...-5.22-3.82%
JAZZJazz Pharmaceuticals...-3.28-3.16%
Data as of 4:03pm ET, 12/07/2016

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)$1.25
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts


Search for Jobs